Durect Corporation (DRRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Durect Corporation (DRRX) has a cash flow conversion efficiency ratio of -0.447x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($3.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Durect Corporation for the company's overall valuation and market capitalisation.
Durect Corporation - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Durect Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Durect Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Durect Corporation ranked by their cash flow conversion efficiency. Explore cash flow quality index of Durect Corporation to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ensurge Micropower ASA
OL:ENSU
|
-0.523x |
|
Nebag ag
SW:NBEN
|
0.006x |
|
Power Metals Corp
V:PWM
|
0.001x |
|
Ageagle Aerial Systems Inc
NYSE MKT:UAVS
|
-0.073x |
|
Phosco Ltd
AU:PHO
|
0.440x |
|
A-Jin Industry Co Ltd
KQ:013310
|
-0.060x |
|
iLearningEngines, Inc.
NASDAQ:AILE
|
-3.216x |
|
Seafire AB
ST:SEAF
|
0.002x |
Annual Cash Flow Conversion Efficiency for Durect Corporation (1999–2024)
The table below shows the annual cash flow conversion efficiency of Durect Corporation from 1999 to 2024. View Durect Corporation stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.13 Million | $-19.09 Million | -2.090x | +10.21% |
| 2023-12-31 | $14.78 Million | $-34.41 Million | -2.328x | -121.32% |
| 2022-12-31 | $24.98 Million | $-26.28 Million | -1.052x | -62.89% |
| 2021-12-31 | $57.78 Million | $-37.31 Million | -0.646x | +33.07% |
| 2020-12-31 | $40.12 Million | $-38.70 Million | -0.965x | -298.68% |
| 2019-12-31 | $22.86 Million | $11.10 Million | 0.486x | +149.18% |
| 2018-12-31 | $20.00 Million | $-19.75 Million | -0.988x | -1480.00% |
| 2017-12-31 | $21.49 Million | $-1.34 Million | -0.063x | +98.09% |
| 2016-12-31 | $8.34 Million | $-27.29 Million | -3.273x | -137.01% |
| 2015-12-31 | $14.88 Million | $-20.55 Million | -1.381x | -79.96% |
| 2014-12-31 | $18.52 Million | $-14.21 Million | -0.767x | -52.62% |
| 2013-12-31 | $30.72 Million | $-15.45 Million | -0.503x | -35.85% |
| 2012-12-31 | $36.33 Million | $-13.45 Million | -0.370x | +92.60% |
| 2011-12-31 | $3.48 Million | $-17.39 Million | -5.000x | -1033.13% |
| 2010-12-31 | $14.49 Million | $7.76 Million | 0.536x | +170.31% |
| 2009-12-31 | $27.42 Million | $-20.89 Million | -0.762x | -194.20% |
| 2008-12-31 | $36.42 Million | $-9.43 Million | -0.259x | +51.04% |
| 2007-12-31 | $34.58 Million | $-18.30 Million | -0.529x | -106.69% |
| 2006-12-31 | $37.03 Million | $-9.48 Million | -0.256x | -53.89% |
| 2005-12-31 | $43.35 Million | $-7.21 Million | -0.166x | +86.23% |
| 2004-12-31 | $18.39 Million | $-22.21 Million | -1.208x | -183.08% |
| 2003-12-31 | $45.12 Million | $-19.25 Million | -0.427x | +9.82% |
| 2002-12-31 | $66.18 Million | $-31.31 Million | -0.473x | -104.69% |
| 2001-12-31 | $97.05 Million | $-22.43 Million | -0.231x | -78.92% |
| 2000-12-31 | $115.25 Million | $-14.89 Million | -0.129x | +63.18% |
| 1999-12-31 | $20.73 Million | $-7.27 Million | -0.351x | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more